ABSTRACT
Pulmonary involvement is common in systemic sclerosis (SSc) and is the most common cause of SSc-related deaths. In particular, the development of pulmonary hypertension (PH) significantly shortens the life span of SSc patients and is fatal if left untreated. Diagnosing PH early and accurately and starting early treatment significantly affects the prognosis of the disease positively. In this article, up-to-date information on SSc associated PH has been reviewed.
References
1
Denton CP, Khanna D. Systemic sclerosis. Lancet 2017;390:1685-99.
2
Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4.
3
Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48:516-22.
4
Almaaitah S, Highland KB, Tonelli AR. Management of Pulmonary arterial hypertension in patients with systemic sclerosis. Integr Blood Press Control 2020;13:15-29.
5
Humbert M, Yaici A, de Groote P, et al. Screening for Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011;63:3522-30.
6
Hinchcliff M, Fischer A, Schiopu E, Steen VD. Pulmonary hypertension assessment and recognition of outcomes in scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol 2011;38:2172-9.
7
Hatano S, Strasser T, eds. Primary Pulmonary Hypertension. Report on a WHO Meeting. Geneva, World Health Organization, 1975.
8
World Health Organization. Chronic cor pulmonale. Report of an expert committee. World Health Organ Tech Rep Ser 1961;213:35.
9
Kovacs G, Berghold A, Scheidl S, et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009;34:888-94.
10
Thomas CA, Anderson RJ, Condon DF, et al. Diagnosis and management of pulmonary hypertension in the modern era: insights from the 6th world symposium. Pulm Ther 2020;6:9-22.
11
Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53:1801913. doi: 10.1183/13993003.01913-2018.
12
Fayed H, Coghlan JG. Pulmonary Hypertension Associated with Connective Tissue Disease. Semin Respir Crit Care Med 2019;40:173-83.
13
Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010;137:376-87.
14
Yang X, Mardekian J, Sanders KN, Mychaskiw MA, Thomas J 3rd. Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. Clin Rheumatol 2013;32:1519-31.
15
Coghlan JG, Denton PC, Grünig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014;73:1340-9.
16
Xanthouli P, Jordan S, Milde N, et al. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. Ann Rheumatic Dis 2019;79:370-8.
17
Nagel C, Marra AM, Benjamin N, et al. Reduced right ventricular output reserve in patients with systemic sclerosis and mildly elevated pulmonary artery pressure. Arthritis Rheumatol 2019;71:805-16.
18
Coghlan JG, Wolf M, Distler O, et al. Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. Eur Respir J 2018;51:1701197. doi: 10.1183/13993003.01197-2017.
19
Launay D, Sobanski V, Hachulla E, Humbert M. Pulmonary hypertension in systemic sclerosis: different phenotypes. Eur Respir Rev 2017;26:170056. doi: 10.1183/16000617.0056-2017.
20
Lambova S. Cardiac manifestations in systemic sclerosis. World J Cardiol 2014;6:993-1005.
21
Fernandez-Codina A, Simeon-aznar CP, Pinal-Fernandez I, et al. Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival. Rheumatol Int 2017;37:75-84.
22
Schoenfeld SR, Castelino FV. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2015;41:237-48.
23
Khanna D, Gladue H, Channick R, et al. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 2013;65:3194-201.
24
Schoenfeld SR, Choi HK, Sayre EC, Avina-zubieta JA. Risk of pulmonary embolism and deep venous thrombosis in systemic sclerosis: a general population-based study. Arthritis Care Res 2016;68:246-53.
25
Bonderman D, Turecek PL, Jakowitsch J, et al. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost 2003;90:372-6.
26
Pepke-zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011;124:1973-81.
27
Aithala R, Alex AG, Danda D. Pulmonary hypertension in connective tissue diseases: an update. Int J Rheum Dis 2017;20:5-24.
28
Thakkar V, Lau EMT, Connective tissue disease-related pulmonary arterial hypertension. Best Pract Res Clin Rheumatol 2016;30:22-38.
29
Frech T, Walker AE, Barrett-o’keefe Z, et al. Systemic sclerosis induces pronounced peripheral vascular dysfunction characterized by blunted peripheral vasoreactivity and endothelial dysfunction. Clin Rheumatol 2015;34:905-13.
30
Schwaiger JP, Khanna D, Gerry Coghlan J. Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations. Eur Respir Rev 2013;22:515-25.
31
Ahearn GS, Tapson VF, Rebeiz A, Greenfield JC Jr. Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease. Chest 2002;122:524-7.
32
Hachulla AL, Launay D, Gaxotte V, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009;68:1878-84.
33
Bezante GP, Rollando D, Sessarego M, et al. Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis. J Rheumatol 2007;34:2431-7.
34
Zompatori M, Leone MB, Giannotta M, et al. Pulmonary hypertension and systemic sclerosis: the role of high-resolution computed tomography. Radiol Med 2013;118:1360-72.
35
Allanore Y, Borderie D, Avouac J, et al. High N-terminal probrain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008;58:284-91.
36
de Camargo VM, do Carmo Dos Santos Martins B, Jardim C, Fernandes CJC, Hovnanian A, Souza R. Validation of a treadmill six-minute walk test protocol for the evaluation of patients with pulmonary arterial hypertension. J Bras De Pneumol 2009;35:423-30.
37
Minai OA, Nguyen Q, Mummadi S, Walker E, McCarthy K, Dweik RA. Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease-associated pulmonary hypertension. Pulm Circ 2015;5:565-76.
38
Gadre A, Ghattas C, Han X, Wang X, Minai O, Highland KB. Sixminute walk test as a predictor of diagnosis, disease severity, and clinical outcomes in scleroderma-associated pulmonary hypertension: the DIBOSA study. Lung 2017;195:529-36.
39
Frost A, Badesch D, Gibbs JSR, et al. Diagnosis of pulmonary hypertension. Eur Respir J 2019;53:1801904. doi: 10.1183/13993003.01904-2018.
40
Huang D, Cheng YY, Chan PH, et al. Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study. ERJ Open Res 2018;4:00135-2017. doi: 10.1183/23120541.00135-2017.
41
Galiè N , Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37:67-119.
42
Thakkar V, Stevens W, Prior D, et al. The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2013;15:R193. doi: 10.1186/ar4383.
43
Hachulla E, Launay D, Boucly A, et al. Survival improved in patients aged ≤ 70 years with systemic sclerosis-associated pulmonary arterial hypertension during the period 2006 to 2017 in France. Chest 2020;157:945-54.
44
Volkov A, Yudkina N, Nikolaeva E, et al. AB0625 Is pulmonary arterial hypertension, associated with systemic sclerosis reversible? Ann Rheum Dis 2020;79:1607-8.
45
Kim N, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019;53:1801915. doi: 10.1183/13993003.01915-2018.
46
Kowal-bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017;76:1327-39.
47
Preston IR, Roberts KE, Miller DP, et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and long-term PAH disease management (REVEAL). Circulation 2015;132:2403-11.
48
Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006;130:182-9.
49
Grunig E, Maier F, Ehlken N, et al. Exercise training in pulmonary arterial hypertension associated with connective tissue diseases. Arthritis Res Ther 2012;14:R148. doi: 10.1186/ar3883.
50
Miniati I, Guiducci S, Mecacci F, Mello G, Matucci-Cerinic M. Pregnancy in systemic sclerosis. Rheumatol 2008;47(Suppl 3):iii16-8. doi: 10.1093/rheumatology/ken174.
51
Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag 2006;2:411-22.
52
Khaybullina D, Patel A, Zerilli T. Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P TPeer-Rev J Formulary Manage 2014;39:749-58.
53
Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007;34:2417-22.
54
Galie N, Denton CP, Dardi F, et al. Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease. Int J Cardiol 2017;235:67-72.
55
Humbert M, Coghlan JG, Ghofrani HA, et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 2017;76:422-6.
56
Raina A, Benza RL, Farber HW. Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series. Pulm Circ 2017;7:741-6.
57
Ghofrani HA, D’Armini AM, Grimminger F, et al. CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013;369:319-29
58
Chester AH, Yacoub MH. The role of endothelin-1 in pulmonary arterial hypertension. Global Cardiology Sci Pract 2014;2014:62-78.
59
Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
60
Fischer A, Denton CP, Matucci-Cerinic M, et al. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial. Respir Med 2016;117:254-63.
61
Rhee RL, Gabler NB, Sangani S, Praestgaard A, Merkel PA, Kawut SM. Comparison of treatment response in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2015;192:1111-7.
62
Del Pozo R, Hernandez Gonzalez I, Escribano-subias P. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. Expert Rev Respir Med 2017;11:491-503.
63
Klings ES, Hill NS, Ieong MH, Simms RW, Korn JH, Farber HW. Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). Arthritis Rheum 1999;42:2638-45.
64
Oudiz RJ, Schilz RJ, Barst RJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004;126:420-7.
65
Caravita S, Wu SC, Secchi MB, Dadone V, Bencini C, Pierini S. Long-term effects of intermittent Iloprost infusion on pulmonary arterial pressure in connective tissue disease. Eur J Intern Med 2011;22:518-21.
66
Gaine S, Chin K, Coghlan G, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J 2017;50:1602493. doi: 10.1183/13993003.02493-2016.
67
Hassoun PM, Zamanian RT, Damico R, et al. Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2015;192:1102-10.
68
Coghlan JG, Galie N, Barbera JA, et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis 2017;76:1219-27.
69
Jansa P, Pulido T. Macitentan in pulmonary arterial hypertension: a focus on combination therapy in the SERAPHIN trial. Am J Cardiovasc Drugs 2018;18:1-11.
70
Coghlan JG, Channick R, Chin K, et al. Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study. Am J Cardiovasc Drugs 2018;18:37-47.
71
Galie N, Muller K, Scalise AV, Grunig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J 2015;45:1314-22.
72
Galie N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019;53:1801889. doi: 10.1183/13993003.01889-2018.
73
Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest 2019;156:323-37.
74
Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-30.
75
Mercurio V, Diab N, Peloquin G, et al. Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: Application of the ESC/ERS risk prediction model. Eur Respir J 2018;52:1800497. doi: 10.1183/13993003.00497-2018.
76
Allcock RJ, O’sullivan JJ, Corris PA. Palliation of systemic sclerosis-associated pulmonary hypertension by atrial septostomy. Arthritis Rheum 2001;44:1660-2.
77
Shah RJ, Boin F. Lung transplantation in patients with systemic sclerosis. Curr Rheumatol Rep 2017;19:23.
78
Schachna L, Medsger TA Jr, Dauber JH, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006;54:3954-61.
79
Attanasio U, Cuomo A, Pirozzi F, et al. Pulmonary hypertension phenotypes in systemic sclerosis: the right diagnosis for the right treatment. Int J Mol Sci 2020;21:4430.
80
Cappelli S, Bellando Randone S, Camiciottoli G, De Paulis A, Guiducci S, Matucci-Cerinic M. Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev 2015;24:411-9.
81
Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019;380:2518-28.
82
Saygin D, Domsic RT. Pulmonary arterial hypertension in systemic sclerosis: challenges ın diagnosis, screening and treatment. Open Access Rheumatol 2019;11:323-33.
83
Clements PJ, Tan M, McLaughlin VV, et al. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis 2012;71:249-52.
84
Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006;54:3043-50.
85
Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009;60:569-77.
86
Bourji KI, Kelemen BW, Mathai SC, et al. Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction. Pulm. Circ 2017;7:409-20.
87
Hurdman J, Condliffe R, Elliot CA, et al. ASPIRE registry: assessing the spectrum of pulmonary hypertension Identified at a referral centre. Eur Respir J 2012;9:945-55.
88
Lefevre G, Dauchet L, Hachulla E, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum 2013;65:2412-23.